Acesion Pharma ApS

Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events, and there is therefore a considerable patient need for developing better and safer drugs. Inhibition of SK channels, an ion channel with relevance for regulating the heart rhythm, constitute a new and promising principle for the treatment of AF.

Contact name:

Ulrik S. Sørensen (CEO)

Address:

Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark

Number of employees:

11

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2016 DANISH BIO – DANSK BIOTEK. All rights reserved.